[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:her2-signaling":3},{"name":4,"total":5,"recruiting":5,"trials":6},"HER2 signaling",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04965064","Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling",[11],"Phase 2","RECRUITING","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.668617Z"]